Skip to content

Class Action Lawsuit Filed Against Replimune Group, Inc: Bragar Eagel & Squire, P.C. Makes Announcement, Encourages Investors to Get in Touch

Lawsuit claims Replimune exaggerated IGNYTE trial prospects, despite flaws; FDA considered trial insufficient, leading to investor losses...

Lawsuit filed against Replimune Group, Inc.: Bragar Eagel & Squire, P.C. notifies investors and...
Lawsuit filed against Replimune Group, Inc.: Bragar Eagel & Squire, P.C. notifies investors and encourages them to make contact

Class Action Lawsuit Filed Against Replimune Group, Inc: Bragar Eagel & Squire, P.C. Makes Announcement, Encourages Investors to Get in Touch

Class Action Lawsuit Filed Against Replimune Group, Inc.

Investors who purchased securities of Replimune Group, Inc. between November 22, 2024, and July 21, 2025, are encouraged to take notice. Bragar Eagel & Squire, P.C., a nationally recognized law firm with offices in New York, California, and South Carolina, has filed a class action lawsuit against Replimune in the United States District Court for the District of Massachusetts.

The lawsuit alleges that defendants made false and/or misleading statements and failed to disclose material information about the company's business, operations, and prospects. Specifically, it claims that defendants recklessly overstated the IGNYTE trial's prospects. When the true details entered the market, investors suffered damages.

Bragar Eagel & Squire, P.C. invites these affected investors to contact Brandon Walker directly to discuss their options. Investors can reach out via email at [email protected], telephone at (212) 355-4648, or by filling out a contact form on the firm's website at www.bespc.com.

Brandon Walker, Esq., along with Marion Passmore, Esq., are attorneys at Bragar Eagel & Squire, P.C. Investors can also follow Brandon Walker on LinkedIn and X.

It's important to note that there is no cost or obligation to contact Bragar Eagel & Squire, P.C. regarding this matter. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

The lawsuit was filed on behalf of all persons and entities who purchased or otherwise acquired Replimune securities during the specified period. Investors who believe they may be eligible to participate in the action can click the provided link for more information.

Bragar Eagel & Squire, P.C. can also be followed for updates on LinkedIn, X, and Facebook. The firm looks forward to helping those who have been affected by these alleged misrepresentations.

Read also: